The report analyzes and presents an overview of Biobetters market worldwide. "Biobetters or Biosuperiors are novel molecules derived from successful, approved biologic products that have been customized to enhance its overall efficacy. The primary characteristics targeted by these applicants include extended half-life in human body, improved bioavailability, lower immunogenicity, higher purity, and fewer side-effects. These molecules contain the same active ingredients such as antibodies to target the same protein, but feature different chemical or molecular properties than the original drug."
The report further discusses about applications, future prospects, and comparison of biobetters with originator drugs and biosimilars along with the strategic industry activities of major companies worldwide. In addition, major companies operating in the Biobetters arena worldwide including Amgen Inc., Cantab Biopharmaceuticals Ltd., Crucell NV, GreenCross Corporation, Hanmi Pharm Co. Ltd., Medgenics Inc., PharmaEssentia Corporation, Polytherics Ltd., SynBio LLC, Teva Pharmaceutical Industries Ltd., Xencor Inc., and others are profiled.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.